InMed Pharmaceuticals Inc. INM
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.94M | 3.25M | 4.51M | 4.80M | 4.94M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.94M | 3.25M | 4.51M | 4.80M | 4.94M |
| Cost of Revenue | 1.35M | 1.35M | 1.35M | 1.37M | 1.42M |
| Gross Profit | 587.40K | 587.40K | 587.40K | 864.10K | 954.30K |
| SG&A Expenses | 7.25M | 6.15M | 6.00M | 6.09M | 6.06M |
| Depreciation & Amortization | 206.50K | 210.30K | 210.30K | 210.30K | 211.70K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.85M | 10.53M | 9.77M | 10.15M | 10.29M |
| Operating Income | -9.91M | -8.59M | -7.83M | -7.92M | -7.91M |
| Income Before Tax | -11.39M | -8.38M | -7.66M | -8.20M | -8.15M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -11.39 | -8.38 | -7.66 | -8.20 | -8.15 |
| Earnings from Discontinued Operations | -1.17M | -128.30K | -7.60K | -7.60K | -7.60K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.56M | -8.51M | -7.66M | -8.21M | -8.16M |
| EBIT | -9.91M | -8.59M | -7.83M | -7.92M | -7.91M |
| EBITDA | -9.71M | -8.38M | -7.63M | -7.71M | -7.70M |
| EPS Basic | -2.78 | -2.88 | -4.08 | -7.21 | -9.48 |
| Normalized Basic EPS | -1.40 | -1.79 | -2.54 | -4.50 | -5.92 |
| EPS Diluted | -2.78 | -2.88 | -4.08 | -7.21 | -9.48 |
| Normalized Diluted EPS | -1.40 | -1.79 | -2.54 | -4.50 | -5.92 |
| Average Basic Shares Outstanding | 17.30M | 13.45M | 10.50M | 7.25M | 3.91M |
| Average Diluted Shares Outstanding | 17.30M | 13.45M | 10.50M | 7.25M | 3.91M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |